Figure 4.

Characterization of protein G-ODN cross-talk. (A) Cetuximab, anti-CD45, and anti-CD31 are labeled in parallel with a unique pG-ODN construct, containing ODN sequences a, b, and c, respectively. Subsequently, the pG-ODN-labeled antibodies are pooled, and cells expressing a specific target protein are incubated with the antibody pool. Eventually, CY5-labeled ODNs, a′, b′, and c′, respectively, complementary to the unique pG-ODN sequence, are used to detect the presence of each antibody on the cell surface. (B) Flow cytometric analysis of three cell lines (A431, Jurkat T cells, and HUVECs) expressing EGFR, CD45, and CD31, respectively. Cells were incubated with 10 nM of the antibody pool containing pG-ODN-labeled Cetuximab, mouse IgG2a anti-CD45, and mouse IgG2a anti-CD31 and subsequently labeled with 100 nM of a CY5-functionalized ODN.